122 related articles for article (PubMed ID: 10466859)
1. Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma.
Schouwink H; Korse CM; Bonfrer JM; Hart AA; Baas P
Lung Cancer; 1999 Jul; 25(1):25-32. PubMed ID: 10466859
[TBL] [Abstract][Full Text] [Related]
2. Cyfra 21-1 and TPA as markers in malignant mesothelioma.
Bonfrer JM; Schouwink JH; Korse CM; Baas P
Anticancer Res; 1997; 17(4B):2971-3. PubMed ID: 9329578
[TBL] [Abstract][Full Text] [Related]
3. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
[TBL] [Abstract][Full Text] [Related]
5. Cyfra 21-1 in monitoring cervical cancer: a comparison with tissue polypeptide antigen and squamous cell carcinoma antigen.
Bonfrer JM; Gaarenstroom KN; Korse CM; Van Bunningen BN; Kenemans P
Anticancer Res; 1997; 17(3C):2329-34. PubMed ID: 9245246
[TBL] [Abstract][Full Text] [Related]
6. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments.
Buccheri G; Torchio P; Ferrigno D
Chest; 2003 Aug; 124(2):622-32. PubMed ID: 12907552
[TBL] [Abstract][Full Text] [Related]
7. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
[TBL] [Abstract][Full Text] [Related]
11. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
13. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.
Fuhrman C; Duche JC; Chouaid C; Abd Alsamad I; Atassi K; Monnet I; Tillement JP; Housset B
Clin Biochem; 2000 Jul; 33(5):405-10. PubMed ID: 11018693
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of the tumor markers TPA-M, CYPFRA 21-1 and CEA in pleural effusion. Prospective comparison of thoracoscopic investigations in patients with pleural effusion].
Riedel U; Schönfeld N; Savaser A; Serk M; Loddenkemper R
Pneumologie; 1999 Oct; 53(10):471-6. PubMed ID: 10596548
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Cyfra 21-1, TPA and SCC tumor markers in esophageal squamous cell carcinoma.
Quillien V; Raoul JL; Laurent JF; Meunier B; Le Prise E
Oncol Rep; 1998; 5(6):1561-5. PubMed ID: 9769406
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin markers in malignant pleural mesothelioma.
Nisman B; Barak V; Heching N; Kramer M; Reinus C; Lafair J
Cancer Detect Prev; 1998; 22(5):416-21. PubMed ID: 9727622
[TBL] [Abstract][Full Text] [Related]
17. Cytokeratin tumor marker levels in bronchial washing in the diagnosis of lung cancer.
Trevisani L; Putinati S; Sartori S; Abbasciano V; Bagni B
Chest; 1996 Jan; 109(1):104-8. PubMed ID: 8549168
[TBL] [Abstract][Full Text] [Related]
18. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group.
Kulpa J; Wójcik E; Radkowski A; Kolodziejski L; Stasik Z
Anticancer Res; 2000; 20(6D):5035-40. PubMed ID: 11326663
[TBL] [Abstract][Full Text] [Related]
19. [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
Inoue C; Kato S; Higuchi K; Inoue H
Nihon Kokyuki Gakkai Zasshi; 2007 Mar; 45(3):243-7. PubMed ID: 17419436
[TBL] [Abstract][Full Text] [Related]
20. Can initial serum cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis?
Gaarenstroom KN; Kenter GG; Bonfrer JM; Korse CM; Van de Vijver MJ; Fleuren GJ; Trimbos JB
Gynecol Oncol; 2000 Apr; 77(1):164-70. PubMed ID: 10739706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]